New study monitors Real-World impact of secukinumab on painful skin condition

NCT ID NCT07282015

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 142 Canadian adults with moderate-to-severe hidradenitis suppurativa who are prescribed secukinumab as part of their regular care. Researchers will track changes in disease severity over 12 months using a standard scoring system. The goal is to understand how well the treatment works in everyday practice and to monitor safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Calgary, Alberta, T2J 7E1, Canada

  • Novartis Investigative Site

    RECRUITING

    Calgary, Alberta, T3E 0B2, Canada

  • Novartis Investigative Site

    RECRUITING

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Novartis Investigative Site

    RECRUITING

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Novartis Investigative Site

    RECRUITING

    St. John's, Newfoundland and Labrador, A1E 1V4, Canada

  • Novartis Investigative Site

    RECRUITING

    Cobourg, Ontario, K9A 4J9, Canada

  • Novartis Investigative Site

    RECRUITING

    Hamilton, Ontario, L8P4B4, Canada

  • Novartis Investigative Site

    RECRUITING

    London, Ontario, N6H 5L5, Canada

  • Novartis Investigative Site

    RECRUITING

    Markham, Ontario, L3P 1X3, Canada

  • Novartis Investigative Site

    RECRUITING

    Mississauga, Ontario, L4W 0C2, Canada

  • Novartis Investigative Site

    RECRUITING

    Richmond Hill, Ontario, L4C 9M7, Canada

  • Novartis Investigative Site

    RECRUITING

    Toronto, Ontario, M4E 1R7, Canada

  • Novartis Investigative Site

    RECRUITING

    Saint-Jérôme, Quebec, J7Z 7E2, Canada

  • Novartis Investigative Site

    RECRUITING

    Sherbrooke, Quebec, J1L 0H8, Canada

  • Novartis Investigative Site

    RECRUITING

    Saskatoon, Saskatchewan, S7N0N5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.